WO1992011870A1 - Method of preventing inflammatory damage - Google Patents
Method of preventing inflammatory damage Download PDFInfo
- Publication number
- WO1992011870A1 WO1992011870A1 PCT/US1992/000178 US9200178W WO9211870A1 WO 1992011870 A1 WO1992011870 A1 WO 1992011870A1 US 9200178 W US9200178 W US 9200178W WO 9211870 A1 WO9211870 A1 WO 9211870A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mol
- binding
- subunit
- neutrophil
- antibody
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000006749 inflammatory damage Effects 0.000 title description 3
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 56
- 102100025390 Integrin beta-2 Human genes 0.000 claims abstract description 27
- 102000006495 integrins Human genes 0.000 claims abstract description 25
- 108010044426 integrins Proteins 0.000 claims abstract description 25
- 241000124008 Mammalia Species 0.000 claims abstract description 18
- 230000001404 mediated effect Effects 0.000 claims abstract description 18
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 15
- 230000006378 damage Effects 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 210000004072 lung Anatomy 0.000 claims abstract description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 5
- 210000004185 liver Anatomy 0.000 claims abstract description 5
- 210000004556 brain Anatomy 0.000 claims abstract description 4
- 210000003734 kidney Anatomy 0.000 claims abstract description 3
- 210000003491 skin Anatomy 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 210000001835 viscera Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 230000008816 organ damage Effects 0.000 abstract description 11
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 abstract 1
- 102100022338 Integrin alpha-M Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 15
- 210000000265 leukocyte Anatomy 0.000 description 12
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 11
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 6
- 206010049771 Shock haemorrhagic Diseases 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 206010021138 Hypovolaemic shock Diseases 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000002981 blocking agent Substances 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010040560 shock Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 2
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 2
- 229960001810 meprednisone Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to reducing or preventing organ damage caused by a neutrophil-mediated inflammatory response.
- neutrophils or polymorphonuclear leukocytes (PMN's)
- PMN's polymorphonuclear leukocytes
- Invasion of the body by infectious bacteria or foreign agents results in a mobilization of the circulating PMN's to the afflicted site in order to limit the spread of infection.
- the initial trigger for this mobilization is provided by certain biochemical factors which may be produced either by the infectious agent or by the host itself. These factors serve to both stimulate and attract the neutrophils into sites of infection or trauma. In response to stimulation by such factors, the neutrophils undergo a number of biochemical and morphological changes to achieve an activated state.
- neutrophils Once in the activated state neutrophils become tightly adherent to endothelial cells lining the capillaries and venules of the microvasculature through which they eventually pass (extravasate) , moving up the gradient of stimulatory factor(s) into the tissue by a process termed chemotaxis.
- the activated neutrophils During their migration toward the source of the stimulatory factors, the activated neutrophils begin to release cytotoxic molecules, such as oxygen radicals and hydrolytic enzymes, as a means of destroying the foreign cells or agents.
- cytotoxic molecules such as oxygen radicals and hydrolytic enzymes
- T Neutrophil stimulating factors can also be produced in the absence of foreign cells or infectious agents.
- ischemia can lead to the production of neutrophil stimulating factors, and PMN's have been shown to be important mediators of the microvascular injury which occurs during reperfusion after periods of low or no blood flow (reperfusion injury) .
- This has been demonstrated in models of occlusion/reperfusion in myocardial infarction as well as with models of hemorrhagic shock which are representative of whole body ischemia.
- neutrophils have been transiently removed or regulated prior to hemorrhagic shock have led to significant improvements in survival and reductions in the failure of sensitive organs such as the gut, liver, and brain secondary to the period of ischemia.
- LFA-1 is the leukocyte integrin exclusively found on the majority of lymphocytes
- pl50,95 is the predominate integrin on macrophages, where no LFA-1 is found.
- integrins All three integrins are found to be present on PMN's and LFA-1 and Mol have each been found to account for about half of the adhesive interaction between neutrophils and endothelium. The role of pl50,95 in this process has not been investigated.
- the primary structure of the leukocyte integrins has been recently determined. As with other integrins, the leukocyte integrins each consist of a non- covalently associated heterodi eric complex of an alpha and a beta subunit. The beta subunit is the product of a single gene and has been previously designated as CD18.
- the three alpha subunits are each distinct gene products and have been designated CDlla (alpha subunit of LFA-1, also ⁇ L) , CDllb (alpha subunit of Mol, also ⁇ M) and CDllc (alpha subunit of pl50,95, also ⁇ X) .
- a beta subunit can thus associate with any of the three alpha subunits to produce an intact and functional molecule.
- U.S. Patent No. 4,797,277 uses antibodies directed to the beta subunit (CD18) of the integrins to reduce tissue damage as evidenced by a reduction in microvascular permeability following hypovolemic shock.
- Wright et al. EP Publication No. 0 346 078 also discloses the use of anti-CD18 antibodies for treating inflammation caused by sepsis or other infectious or non-infectious trauma.
- Mileski (Surgery, 1990, 2___8 ⁇ 206-212) uses anti-CD18 antibodies to reduce PMN-mediated organ injury after hemorrhagic shock in primates. Vedder et a!
- Todd et al. U.S. Patent Nos. 4,935,234 and 4,840,793, hereby incorporated by reference, use an antibody specifically targeted to Mol (anti-CDllb) , designated MY904, to reduce tissue damage in a canine model of myocardial infarction.
- Ismail et al. (Blood, 1987, 6 :1167-1174) describe use of an anti-Mol antibody for prevention of pulmonary injury ex vivo in rat lungs perfused with activated human neutrophils.
- the Todd et al. work with canine myocardial infarction is not predictive of the effect of anti-CDllb antibodies in other organs, as much evidence suggests that the heart may be unigue.
- cardiac myocytes produce ICAM-1 on their surface under certain conditions of stress. Neutrophils can adhere to myocytes by interacting with the expressed ICAM-1, and this interaction can be blocked by anti-CDllb antibodies but not anti-CDlla antibodies. This difference cannot be demonstrated when ICAM-1 is expressed on endothelial cells, where binding is mediated by both CDlla/CD18 and CDllb/CD18. This suggests that the ICAM-1 expressed on cardiac myocytes is unique and distinct from ICAM-1 expressed on endothelial cells. In addition, while it is generally expressed on endothelial cells and fibroblasts, ICAM-1 expression has not been demonstrated in organ - specific cells other than cardiac myocytes.
- the invention provides a method for inhibiting activated neutrophil-mediated damage to the gut, liver, kidneys, skin, brain, or lungs of a mammal resulting from blood loss followed by transfusion; the method involves administering to the mammal (preferably a human patient) , at the time of or following transfusion (preferably within one hour of transfusion) an organ damage-inhibiting amount of an antibody capable of
- administration is carried out by mixing the antibody with the transfused fluid so that the two are administered together, in mixed form.
- transfusion intravenous infusion into a patient of whole blood, plasma, synthetic blood substitutes, or other fluid, following significant blood loss, in particular hemorrhagic blood loss.
- Suitable antibodies are MAb 17 and MY904; MY904 is publicly available (MY904 is described, e.g., in U.S. Patent No. 4,935,234, supra..
- blocking of the CDllb subset of adhesion molecules alone is sufficient to prevent neutrophil-mediated organ damage caused by transfusion following significant blood loss.
- Anti-CDllb antibodies will not impair the functions of LFA-1 and pl50,95 integrins, the blockage of which could have potential adverse effects due to the involvement of these receptors in normal immunological function and wound healing, respectively.
- the invention therefore, provides significant advantages over therapy using anti- CD18 antibodies.
- the inhibition of neutrophil-mediated damage may be observed as a protection from actue organ failure and/or as a protection from bacterial sepsis occurring later as a result of bacterial translocation across the damaged gut or lung mucosal barrier.
- the invention features a method of inhibiting activated neutrophil-mediated damage to an internal organ of a mammal resulting from surgery on the mammal at a locus other than the organ; the method involves administering to the mammal prior to, during, or following the surgery an organ damage-inhibiting amount of an antibody capable of binding to the CDllb subunit of the neutrophil integrin Mol, and being substantially incapable of binding to the CD18 subunit of Mol.
- Administration of the antibody can be carried out by intravenous injection of a bolus just prior to surgery, or during surgery, by mixing the antibody with other IV fluids administered gradually to the surgical patient.
- systemic organ damage that can occur during surgery, particularly in compromised patients is reduced by the systemically administered antibody.
- the method is particularly useful in prevention of Adult Respiratory Distress Syndrome (ARDS) , which is a common and serious complication of surgical procedures on compromised patients, particularly cigarette smokers, cancer patients whose immune systems are suppressed because of chemotherapy or radiation, and patients infected with microbial pathogens.
- ARDS Adult Respiratory Distress Syndrome
- the invention features inhibition of activated neutrophil-mediated inflammation in a mammal by administering to the mammal two synergistically acting anti-inflammatory agents, the first being an anti-CDllb antibody as described above, and the second being an agent which interferes with the process of neutrophil activation; the two agents are administered together, or close enough in time so that they act synergistically.
- neutrophil activation-blocking agents are methylprednisone, ibuprofen, and pentoxifylline. This method is particularly useful in prevention of inflammation resulting from blood loss followed by transfusion, and in preventing systemic inflammation resulting from surgery.
- the invention features the method of treating sepsis in a mammal by administering to the mammal two synergistically acting sepsis-inhibiting agents, the first of which is an anti-CDllb antibody as discussed above, and the second of which is an agent which blocks the action of a pathogen-mediated activator of inflammation; the first and second agents are administered together, or close enough in time so that they act synergistically.
- the second, inflammation activator-blocking agent is an antibody, e.g. , one specific for bacterial lipopolysaccharide, or - 1 - one which binds specifically to a mammalian inflammation activator, e.g., tumor necrosis factor (described in EP Appln. No. 0351789) , whose release from mammalian cells is triggered by a pathogen.
- the method of the present invention involves administration of antibodies directed against the CDllb subunit of the Mol glycoprotein to prevent or inhibit generalized or systemic neutrophil-mediated inflammatory damage in organs other than the heart resulting from blood loss followed by transfusion.
- the invention makes possible the early treatment or prevention of inflammatory episodes to prevent such episodes from progressing into serious conditions resulting in organ damage or immune paralysis.
- the protective effect provided by the anti-CDllb antibody can be described as follows.
- Hemorrhagic shock or hypovolemic shock occurring from transient blood loss followed by transfusion, leads to damage to gut, liver, lung, and brain. Organ failure related to this damage is frequently irreversible and can result in death.
- the previously demonstrated protective effect of adhesion- blocking anti-CD18 antibodies and neutrophil depletion in hemorrhagic shock confirms that neutrophils play a role in the pathogenesis of this disorder.
- the mechanisms by which neutrophils become activated in hemorrhagic shock have been shown to be multiple and include complement activation and the production of inflammatory cytokines such as TNF-alpha and IL-6.
- Antibodies to CD18 which block or alter leukocyte adhesion affect all three leukocyte integrins equally.
- ICAM-1 which is expressed on endothelial and certain other cells, is a ligand for both LFA-1 and Mol. ICAM-1 is believed to be important in mediating neutrophil adhesion and extravasation and is increased during periods of inflammation. A second ligand, ICAM-2, is only bound by LFA-1 and not by Mol. The role of ICAM-2 in the inflammatory process is not well understood. Other ligands for LFA-1 and Mol may also exist but have not yet been identified. At present, no ligand for pl50,95 has been unambiguously identified. The complexity of the leukocyte integrins' interaction with their various cognate ligands means that it cannot be known whether blockade of any single integrin or ligand would be sufficient to inhibit organ damage.
- the invention can employ any antibody capable of specifically binding to the CDllb subunit of the Mol neutrophil cell surface receptor.
- Such specifically- binding antibodies can block one or more relevant, potentially organ-damaging neutrophil functions including (1) the interaction between the neutrophil and vascular endothelium which initiates the influx of the neutrophils into the extravascular tissue, (2) the production of deleterious reactive oxygen intermediates by the neutrophil NADPH oxidase, and (3) the homotypic aggregation of the neutrophils which can impede microvascular flow.
- the particular antibody utilized in the examples described below is a monoclonal antibody identified as MAb 17.
- MAb 17 was made by scientists at the Dana- Farber Cancer Institute, Boston, MA, by immunizing female Balb/C mice with cells from the peripheral blood of an adult patient with monocytic leukemia using the standard procedures described by Kohler and Milstein (Nature, 1975, 256:495-497) . Specifically, mice were injected intraperitoneally with 20 x 10 6 cells, and were boosted at weekly intervals for 4 weeks with 20 x 10 6 cells and for an additional 2 weeks with 15 x 10 6 cells. Four days following the final boost, the spleen was removed and a single cell suspension was made of the splenocytes.
- the cells were mixed with mouse myeloma NS-1 cells and monoclonal antibody-producing hybridoma clones were characterized by their ability to block neutrophil aggregation and other Mol ependent adhesive interactions in both human and rat cells.
- MAb 17 was identified as an antibody of the IgM isotype that reacts with neutrophils, monocytes, macrophages and certain NK cells.
- monoclonal antibodies useful in the method of the invention can be made by immunizing mice with human neutrophils or monocytes, fusing the murine spleen cells with appropriate fusion partners, and screening the antibodies produced by the resultant hybridoma lines for the ability to bind, and the failure to bind the CD18 subunit thereof.
- other cells known to express the leukocyte CDllb/CD18 complex can be used as immunogens.
- monocytes are used for hybridoma formation, a dual screening process can be carried out. In the first step, antibodies are screened for their ability to bind human granulocytes and monocytes, but not normal T-lymphocytes,
- B-lymphocytes or red blood cells.
- Those selected in the first screening assay are then evaluated for their ability to demonstrate a 6 to 8 fold increase in reactivity with human neutrophils activated with f- MetLeuPhe.
- Selected antibodies are finally screened for the ability to inhibit both neutrophil adhesion to plastic surfaces and homotypic neutrophil aggregation induced by neutrophil activating factors.
- Monoclonal antibody MY904 can also be used.
- MY904 is on deposit with the American Type Culture Collection (ATCC) and is assigned ATCC Accession Number HB 9510.
- Antibodies exhibiting the binding specificity of MY904 can be made according to the procedure described for making MY904 in Todd et al. U.S. Patent No. 4,935,234, supra.
- the invention can employ not only intact antibody molecules, e.g. , intact monoclonal or polyclonal antibodies, but also an immunologically-active antibody fragment, for example, the Fab fragment or the (Fab) 2 fragment; an antibody heavy chain; an antibody light chain; a genetically engineered single-chain F v molecule; or a chimeric antibody, for example, an antibody which contains the binding specificity of a murine antibody, but in which the remaining portions of the antibody are of human origin. In general, it may be advantageous to modify the antibody to be more compatible with human use.
- MAb 17, a murine IgM which is specific for the CDllb subunit of the Mol receptor on human neutrophils may be converted into a (Fab) 2 fragment which retains the same binding properties as the intact antibody but which does not have the disadvantages associated with the immunologic effector functions carried by the Fc portion of the antibody.
- Therapy Sufficient antibody is provided to prevent substantial organ damage which would otherwise result from substantial blood loss followed by transfusion, or systemic organ damage resulting from surgery at a locus other than the organ. Typically, this may be achieved with doses of from about 1 to about 10 mg/kg. The preferred dosage is in the range 1-2 mg/kg.
- the invention is primarily concerned with the treatment of humans and administration is preferably systemic, i.e., the antibody is administered in such a way that it can reach the circulation without being substantially inactivated. Most preferably, the antibody is added to the transfusion fluid prior to or during transfusion, or with other fluids, administered prior to or during surgery.
- anti-CDllb antibody is provided in the doses described above.
- the second agent is a neutrophil activation blocking agent, such as methylprednisone, ibuprofen or pentoxyfylline
- dosages can be those typically used for use of these agents in known therapies.
- doses of from about 1 to about 25 mg/kg; preferably about 10 to about 20 mg/kg can be used.
- the second agent is an antibody which blocks the action of a pathogen-mediated activator of inflammation
- doses of from about 1 to about 25 mg/kg; preferably in the range of from about 10 to about 20 mg/kg can be used.
- the specific dose will be dependent on the circulating half-life of the particular antibody and will generally be determined by providing an amount sufficient to maintain about 2-20 ug/ l in the blood.
- the methods of the invention may be used to limit inflammatory responses in any mammal, for example, humans, domestic pets, or livestock. Where a non-human mammal is treated, the antibody employed is preferably specific for that species.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4505314A JPH06505969A (en) | 1991-01-11 | 1992-01-10 | How to prevent inflammatory damage |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64007191A | 1991-01-11 | 1991-01-11 | |
US640,071 | 1991-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992011870A1 true WO1992011870A1 (en) | 1992-07-23 |
Family
ID=24566733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/000178 WO1992011870A1 (en) | 1991-01-11 | 1992-01-10 | Method of preventing inflammatory damage |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0565642A1 (en) |
JP (1) | JPH06505969A (en) |
CA (1) | CA2100084A1 (en) |
WO (1) | WO1992011870A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646251A (en) * | 1993-11-05 | 1997-07-08 | The Board Of Trustees Of Leeland Stanford Jr. Univ. | Alloreaction-associated antigen (ARAG): a novel member of the immunoglobulin gene superfamily |
US5708141A (en) * | 1992-05-11 | 1998-01-13 | Corvas International, Inc. | Neutrophil inhibitors |
US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US5985279A (en) * | 1991-07-16 | 1999-11-16 | Waldmann; Herman | Humanized antibody against CD18 |
US6156878A (en) * | 1994-02-10 | 2000-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
US6663863B2 (en) | 2000-03-17 | 2003-12-16 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2252629A1 (en) * | 1997-02-26 | 1998-09-03 | Toray Industries, Inc. | Remedies for hepatitis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0346078A2 (en) * | 1988-06-07 | 1989-12-13 | The Rockefeller University | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma |
EP0351789A2 (en) * | 1988-07-18 | 1990-01-24 | Chiron Corporation | Improved monoclonal antibodies reactive with cachectin |
US4935234A (en) * | 1987-06-11 | 1990-06-19 | Dana-Farber Cancer Institute | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
-
1992
- 1992-01-10 EP EP92905038A patent/EP0565642A1/en not_active Withdrawn
- 1992-01-10 CA CA002100084A patent/CA2100084A1/en not_active Abandoned
- 1992-01-10 JP JP4505314A patent/JPH06505969A/en active Pending
- 1992-01-10 WO PCT/US1992/000178 patent/WO1992011870A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935234A (en) * | 1987-06-11 | 1990-06-19 | Dana-Farber Cancer Institute | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
EP0346078A2 (en) * | 1988-06-07 | 1989-12-13 | The Rockefeller University | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma |
EP0351789A2 (en) * | 1988-07-18 | 1990-01-24 | Chiron Corporation | Improved monoclonal antibodies reactive with cachectin |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689869B2 (en) | 1991-07-16 | 2004-02-10 | Cambridge University Technical Services Limited | Labeled humanized anti-CD18 antibodies and fragments and kits comprising same |
US5985279A (en) * | 1991-07-16 | 1999-11-16 | Waldmann; Herman | Humanized antibody against CD18 |
US5997867A (en) * | 1991-07-16 | 1999-12-07 | Waldmann; Herman | Method of using humanized antibody against CD18 |
US5708141A (en) * | 1992-05-11 | 1998-01-13 | Corvas International, Inc. | Neutrophil inhibitors |
US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US7364733B2 (en) | 1993-11-03 | 2008-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody to receptor on the surface of activated T-cells: ACT-4 |
US6277962B1 (en) | 1993-11-03 | 2001-08-21 | The Board Of Trustees Of Leland Stanford Junior University | Receptor on the surface of activated t-cells: act-4 |
US5646251A (en) * | 1993-11-05 | 1997-07-08 | The Board Of Trustees Of Leeland Stanford Jr. Univ. | Alloreaction-associated antigen (ARAG): a novel member of the immunoglobulin gene superfamily |
US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
US6528623B2 (en) | 1994-02-10 | 2003-03-04 | The Board Of Trustees Of The Leland Stanford Junior University | Antibodies that specifically bind ACT-4-L-h-1 ligand |
US7098184B2 (en) | 1994-02-10 | 2006-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating rheumatoid arthritis and multiple sclerosis diseases of the human immune system |
US7125670B2 (en) | 1994-02-10 | 2006-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+T-cells |
US6156878A (en) * | 1994-02-10 | 2000-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
US6663863B2 (en) | 2000-03-17 | 2003-12-16 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis |
Also Published As
Publication number | Publication date |
---|---|
JPH06505969A (en) | 1994-07-07 |
CA2100084A1 (en) | 1992-07-12 |
EP0565642A1 (en) | 1993-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HAUG et al. | A Phase I Trial Of Immunosuppression With Antiic Am-1 (Cd54) mAb In Renal Allograft Recipients | |
EP0625912B1 (en) | Treatment for inflammatory bowel disease | |
Mulligan et al. | Roles of beta 2 integrins of rat neutrophils in complement-and oxygen radical-mediated acute inflammatory injury. | |
Symon et al. | Eosinophil adhesion to nasal polyp endothelium is P-selectin-dependent. | |
EP2040730B1 (en) | Modulation of nkg2d in hbv patients | |
JP2018512850A (en) | Novel recombinant bifunctional fusion protein and its preparation and application | |
AU2008202838A1 (en) | Combination therapy | |
AU2012383254A1 (en) | Method for treating a GD2 positive cancer | |
KR100470739B1 (en) | Lymphtoxin-α / β Complexes and Anti-lymphotoxin-β Receptor Antibodies as Antitumor Agents | |
CA2134966C (en) | Antibodies with specificity for multiple adhesion molecules | |
SK77393A3 (en) | Pharmaceutical mixture for treatment of illnesses by inhibition of intercellular adhesion by elam-1 | |
US4731244A (en) | Monoclonal antibody therapy | |
Alters et al. | Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies. | |
Fletcher et al. | C5a-induced myocardial ischemia: role for CD18-dependent PMN localization and PMN-platelet interactions | |
Keystone | B cells in rheumatoid arthritis: from hypothesis to the clinic | |
WO1992011870A1 (en) | Method of preventing inflammatory damage | |
AU2019235626A1 (en) | Combination of CD47 blockade therapy and a CD38 antibody | |
US5855888A (en) | Drug for the treatment of rheumatoid arthritis | |
WO1995013093A1 (en) | Treatment of a patient prior to transplantation | |
Norman | The clinical role of OKT3 | |
Ludwig et al. | Platelet, not endothelial, P-selectin expression contributes to generation of immunity in cutaneous contact hypersensitivity | |
Todd III et al. | Anti-Inflammatory Properties of Monoclonal Anti-Mo1 (CD11b/CD18) Antibodies In Vitro and In Vivo | |
US20220135695A1 (en) | Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants | |
Pathy | Patent Evaluation on Monoclonal Antibody (MAB) Therapy with Binding Specificity to CD20 B-Cell Surface Antigen Bp35 and the Manufacturing Process of Biological & Antibodies and Derivatives | |
EP0791360A2 (en) | Treatment of septic shock with anti-TNF antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2100084 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992905038 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992905038 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992905038 Country of ref document: EP |